Al-Barshomy, S., Ghorab, A., Mahmoud, O., Shahein, M., Mahmoud, A., Sakla, N. (2021). Value of Serum Copeptin Estimation for the Diagnosis of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients. The Egyptian Journal of Hospital Medicine, 84(1), 2242-2248. doi: 10.21608/ejhm.2021.181217
said M Al-Barshomy; Adel A. Ghorab; Osama A. Mahmoud; Mohamed Shahein; Amira A. Mahmoud; Niveen S.S. Sakla. "Value of Serum Copeptin Estimation for the Diagnosis of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients". The Egyptian Journal of Hospital Medicine, 84, 1, 2021, 2242-2248. doi: 10.21608/ejhm.2021.181217
Al-Barshomy, S., Ghorab, A., Mahmoud, O., Shahein, M., Mahmoud, A., Sakla, N. (2021). 'Value of Serum Copeptin Estimation for the Diagnosis of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients', The Egyptian Journal of Hospital Medicine, 84(1), pp. 2242-2248. doi: 10.21608/ejhm.2021.181217
Al-Barshomy, S., Ghorab, A., Mahmoud, O., Shahein, M., Mahmoud, A., Sakla, N. Value of Serum Copeptin Estimation for the Diagnosis of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients. The Egyptian Journal of Hospital Medicine, 2021; 84(1): 2242-2248. doi: 10.21608/ejhm.2021.181217
Value of Serum Copeptin Estimation for the Diagnosis of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Background: Serum copeptin, the terminal part of the arginine vasopressin (AVP), is stable in plasma. The AVP is increased in diabetic patients and may play a role in the development of diabetic kidney disease. Objective: To evaluate the role of serum copeptin in the diagnosis of diabetic nephropathy in type-2 diabetes mellitus. Patients and Methods: 40 type-2 diabetes mellitus (T2DM) patients; divided into two groups, (20 with poor glycemic control, and 20 with good glycemic control), in addition to 20 non-diabetic healthy control subjects. The following investigations had been made; HbA1C, FBS, blood urea, serum creatinine and sodium, creatinine clearance (Ccr), glomerular filtration rate (eGFR), urinary protein, and urinary sodium. Serum copeptin levels were measured using an enzyme-linked immunoassay (ELISA). Results: Serum copeptin levels were significantly higher in (T2DM) patients with poor glycemic control than in (T2DM) patients with good glycemic control compared to the healthy control group. There was a significant positive correlation between serum copeptin and FBS, HbA1C, blood urea, serum creatinine, urinary Na, and 24-hour urinary protein, and a significant negative correlation with serum Na, eGFR, and creatinine clearance. The receiver operating characteristic (ROC) curve for the validity of serum copeptin, as a marker for diabetic nephropathy, at cutoff point 3452 pg/ml, showed 90% sensitivity, and 95% specificity. Conclusion: Serum copeptin is independently related to markers of kidney injury in T2DM and may be used as a marker for diabetic nephropathy.